BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 10, 2019
View Archived Issues
Nicotinamide riboside shows promise for myocardial infarction
Read More
Parasite protects T cells from HIV
Read More
Cheerful gut bug has relationship with antidepressant
Read More
Experimental model developed for PACAP-induced headache
Read More
Phospholipase D inhibitors developed for testing in neurodegeneration models
Read More
Aptorum announces updates in preclinical pipeline
Read More
Lilly reports promising results from phase I/II study of selpercatinib in RET fusion-positive NSCLC
Read More
Results from phase II ADAMANT trial of AADvac-1 in Alzheimer's disease reported
Read More
Cassava Sciences announces phase IIa data for PTI-125 in Alzheimer's disease
Read More
Preclinical characterization of novel mGlu2 receptor PAMs for the treatment of substance abuse
Read More
PCYT2 as a novel disease gene for complex hereditary spastic paraplegia
Read More
RINT1 biallelic variants linked to recurrent acute liver failure and skeletal anomalies
Read More
New TRPC6 antagonists identified at Boehringer Ingelheim
Read More
Vertex Pharmaceuticals patents CFTR modulators
Read More
Newave Pharmaceutical presents Bruton tyrosine kinase inhibitors
Read More
Dana-Farber Cancer Institute describes new IRAK degraders
Read More
New P300/CBP HAT inhibitors identified at Constellation Pharmaceuticals
Read More
Potential target identified for leukemia treatment
Read More
Phase II data on contezolid acefosamil in ABSSSI support progression to phase III trials
Read More
Phase II study of bryostatin-1 in moderate to severe Alzheimer's misses primary endpoint
Read More
Prometic initiates phase I study of PBI-4547
Read More
Alector begins phase II study of AL-001 for frontotemporal dementia
Read More
Translate Bio discontinues MRT-5201 for OTC deficiency, prioritizes pulmonary disease programs
Read More
Pfizer reports preliminary data from phase II pediatric study of 20vPnC candidate
Read More
